Leerink Partnrs Issues Negative Outlook for Certara Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Stock analysts at Leerink Partnrs decreased their Q2 2025 earnings estimates for shares of Certara in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.06 per share for the quarter, down from their previous estimate of $0.07. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2027 earnings at $0.38 EPS.

Several other research firms have also recently weighed in on CERT. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Morgan Stanley initiated coverage on shares of Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price target for the company. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Finally, KeyCorp upped their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.71.

Certara Price Performance

NASDAQ CERT traded down $0.41 during trading hours on Thursday, hitting $11.09. 875,697 shares of the company's stock traded hands, compared to its average volume of 1,472,008. The firm's 50-day moving average is $11.42 and its 200-day moving average is $11.88. Certara has a 52-week low of $8.64 and a 52-week high of $16.93. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. The company has a market capitalization of $1.80 billion, a PE ratio of -554.50 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. During the same quarter in the prior year, the company earned $0.10 EPS. Certara's revenue was up 9.7% compared to the same quarter last year.

Institutional Investors Weigh In On Certara

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its holdings in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after buying an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Certara during the 1st quarter worth approximately $31,000. Wells Fargo & Company MN lifted its holdings in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares in the last quarter. AlphaQuest LLC acquired a new stake in Certara during the 1st quarter worth approximately $39,000. Finally, Johnson Financial Group Inc. acquired a new stake in Certara during the 4th quarter worth approximately $47,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.